Compared with placebo, curcumin was associated with a significant reduction in
liver fat content (78.9% improvement in the curcumin vs 27.5% improvement in the placebo group). There were
also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein
cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated
hemoglobin compared with the placebo group. Curcumin was safe and well tolerated during the course of trial.
Findings of the present proof-of-concept trial suggested improvement of different features of NAFLD after a
short-term supplementation with curcumin